Below are the most recent publications written about "Injections, Intramuscular" by people in Profiles.
-
Cardoso KF, de Souza LRA, Martins DS, da Silva Santos BS?, de Carvalho KRA, da Silva Messias SG, de Faria Gon?alves AP, Do Nascimento Mac?rio RR, de Jesus DJF, De Mendon?a ?ngelo ALP, de Paula Pereira L, Nascimento SLM, Kano FS, Alves PA, Xavier MAP, Martins-Filho OA, Russo RC, Gazzinelli RT, Miyaji EN, Garcia CC, de Magalh?es Vieira Machado A, Ara?jo MSS. Safety and efficacy of an intramuscular bivalent vaccine against influenza and Streptococcus pneumoniae infections in mice. Med Microbiol Immunol. 2025 Aug 29; 214(1):39.
-
Rwebembera J, Ndagire E, Carvalho N, Webel AR, Sable C, Okello E, Sarnacki R, Spaziani AM, Mucunguzi A, Engelman D, Grobler A, Steer A, Beaton A. Intramuscular versus enteral penicillin prophylaxis to prevent progression of rheumatic heart disease: Study protocol for a noninferiority randomized trial (the GOALIE trial). Am Heart J. 2024 Sep; 275:74-85.
-
Beaton A, Okello E, Rwebembera J, Grobler A, Engelman D, Alepere J, Canales L, Carapetis J, DeWyer A, Lwabi P, Mirabel M, Mocumbi AO, Murali M, Nakitto M, Ndagire E, Nunes MCP, Omara IO, Sarnacki R, Scheel A, Wilson N, Zimmerman M, Z?hlke L, Karthikeyan G, Sable CA, Steer AC. Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease. N Engl J Med. 2022 01 20; 386(3):230-240.
-
Shirk SD, Ameral V, Kraus SW, Houchins J, Kelly M, Pugh K, Reilly E, Desai N. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A?Retrospective Chart Review. J Dual Diagn. 2021 Jul-Sep; 17(3):207-215.
-
Cunningham C, Gross K, Broach JP, O'Connor L. Patient Outcomes Following Ketamine Administration for Acute Agitation with a Decreased Dosing Protocol in the Prehospital Setting. Prehosp Disaster Med. 2021 Jun; 36(3):276-282.
-
Pivovarova E, Min HS, Friedmann PD. Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders. Subst Abus. 2021; 42(4):618-624.
-
Gernoux G, Gruntman AM, Blackwood M, Zieger M, Flotte TR, Mueller C. Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans. Mol Ther. 2020 03 04; 28(3):747-757.
-
Afkhami S, Lai R, D'agostino MR, Vaseghi-Shanjani M, Zganiacz A, Yao Y, Jeyanathan M, Xing Z. Single-Dose Mucosal Immunotherapy With Chimpanzee Adenovirus-Based Vaccine Accelerates Tuberculosis Disease Control and Limits Its Rebound After Antibiotic Cessation. J Infect Dis. 2019 09 13; 220(8):1355-1366.
-
Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Zhang Y, Tolley E, Sugarman J, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Spreen WR, Cohen MS, McCauley M, Eron JJ. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018 11; 15(11):e1002690.
-
Springer SA, Di Paola A, Azar MM, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial. J Acquir Immune Defic Syndr. 2018 05 01; 78(1):43-53.